

MATERIAL SAFETY DATA SHEET

Product Name: Naloxone Hydrochloride Injection, USP

1. CHEMICAL PRODUCT AND COMPANY INFORMATION

Manufacturer Name And Address Hospira, Inc. 275 North Field Drive Lake Forest, Illinois 60045 USA

Emergency Telephone Hospira, Inc. CHEMTREC: 800 424-9300 224 212-2055

Product Name

Naloxone Hydrochloride Injection, USP

Synonyms

None

2. COMPOSITION/INFORMATION ON INGREDIENTS

Ingredient Name Chemical Formula Naloxone Hydrochloride $C_{19}H_{22}ClNO_4$

Component	Approximate Percent by Weight	CAS Number	RTECS Number
Naloxone Hydrochloride	0.04	357-08-4	QD2275000
Sodium Chloride	0.9	7647-14-5	VZ4725000
Water	99	7732-18-5	ZC0110000

	3. HAZARD INFORM	ATION	
• • •	Emergency Overview	In clinical use, this material is used to reverse the effects Possible target organs include the nervous system and ca	
	Occupational Exposure Potential	Information on the absorption of this compound via inge inhalation or skin contact is not available. Avoid liquid a skin contact.	
	Signs and Symptoms	No signs or symptoms from occupational exposure are kn suggest the following: drowsiness, altered blood pressure edema, increased blood pressure, memory lapse, numbre gastrointestinal upset, mood changes.	, cardiac changes,
	Medical Conditions Aggravated by Exposure	Hypersensitivity to the material and/or similar materials. in the following organs: nervous system, cardiovascular	9

Product Name: Naloxone Hydrochloride Injection, USP

4. FIRST AID MEA	ASURES
Eye Contact:	Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.
Skin Contact:	Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.
Inhalation:	Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic / supportive care as necessary.
Ingestion:	Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic / supportive care as necessary.

Flammability:	Non-flammable		
Fire & Explosion Hazard:	None		
Extinguishing Media:	Use extinguishing media appropriate for primary cause of fire.		
Special Fire Fighting Procedures	No special provisions required beyond normal fire fighting equipment such as flame and chemical resistant clothing and self contained breathing apparatus.		

6. ACCIDENTAL RELEASE MEASURES

Spill Cleanup and DisposalAbsorb with suitable material and clean affected area with soap and water.
Dispose of materials according to the applicable federal, state, or local
regulations.

7. HANDLING AND STORAGE			
Handling	Protect from light by retaining in carton until contents have been used.		
Storage	No special storage required for hazard control. For product protection store at controlled room temperature of 15-30°C (59-86°F).		
	Detection for the little set and have		

Special Precautions Protect from freezing, light and extreme heat.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Exposure Guidelines

		Exposure limits	ts		
Component	OSHA-PEL	ACGIH-TLV	Hospira EEL		
Naloxone Hydrochloride	8 hr TWA: Not Established	8 hr TWA: Not Established	8 hr TWA: 1 mg/m3 STEL: Not Established		
Sodium Chloride	8 hr TWA: Not Established	8 hr TWA: Not Established	8 hr TWA: Not Established STEL: Not Established		

Notes: OSHA PEL: US Occupational Safety and Health Administration - Permissible Exposure Limit

ACGIH TLV: American Conference of Governmental Industrial Hygienists - Threshold Limit Value.

EEL: Employee Exposure Limit.

TWA: 8 hour Time Weighted Average.

STEL: 15-minute Short Term Exposure Limit.

Product Name: Naloxone Hydrochloride Injection, USP

Respiratory Protection	Respiratory protection is not needed during normal product use.
Skin Protection	If solution contact with unprotected skin is likely, use of impervious gloves is a prudent practice.
Eye Protection	Eye protection is not required during expected product use conditions but may be warranted should a splash potential exist.
Engineering Controls	Engineering controls are not needed during normal product use conditions.

9. PHYSICAL/CHEMICAL PROPERTIES

Appearance/Physical State Odor Boiling Point Freezing Point Vapor Pressure Vapor Density (Air=1) Evaporation Rate Bulk Density Specific Gravity Solubility pH Clear liquid

None Approximately that of water (100 °C, 212 °F). Approximately that of water (0 °C, 32 °F). Approximately that of water (17.5 mm Hg at 20 °C). Not Applicable Not Applicable Not Determined Approximately that of water (1.0). Water 3.0-4.5

10. STABILITY AND REACTIVITY

Chemical Stability	Stable under standard use and storage conditions.
Incompatibilities	Narcotics
Hazardous Decomposition Products	Toxic fumes of nitrogen oxides and HCl.
Hazardous Polvmerization	Not Determined.

11. TOXICOLOGICAL INFORMATION:

Acute Toxicity – Oral:					
Ingredient(s)	Percent	Test Type	Value	Units	Species
Naloxone Hydrochloride	100	LD50	1000	mg/kg	Rats, Mice

LD50: Dosage needed to produce 50% mortality.

Product contains approximately 0.04% Naloxone Hydrochloride.

Mutagenicity Not Determined

Target Organ Effects

Not Determined

In clinical use target organ effects include nervous system and cardiovascular system.

12. ECOLOGICAL INFORMATION:

Aquatic Toxicity

Not Available

13. DISPOSAL CONSIDERATIONS:

 Waste Disposal
 Disposal should be performed in accordance with the federal, state or local regulatory requirements.

Container Handling and Disposal Dispose of container and unused contents in accordance with federal, state, and local regulations.

14. TRANSPORTATION INFORMATION

DOT

Not Regulated

Notes: DOT - US Department of Transportation Regulations

15. REGULATORY INFORMATION

TSCA Status CERCLA Status SARA Status RCRA Status PROP 65 (Calif.) Not Regulated Not Regulated Not Regulated Not Regulated Not Regulated

Notes: TSCA Toxic Substance Control Act CERCLA, US EPA law, Comprehensive Environmental Response, Compensation, and Liability Act SARA Superfund Amendments and Reauthorization Act RCRA US EPA, Resource Conservation and Recovery Act Prop 65, California Proposition 65

16. OTHER INFORMATION:

MSDS CoordinatorGlobal Occupational ToxicologyDate PreparedSeptember 15, 2005Date RevisedOctober 21, 2008

Disclaimer:

The information and recommendations contained herein are based upon tests believed to be reliable. However, Hospira does not guarantee their accuracy or completeness NOR SHALL ANY OF THIS INFORMATION CONSTITUTE A WARRANTY, WHETHER EXPRESSED OR IMPLIED, AS TO THE SAFETY OF THE GOODS, THE MERCHANTABILITY OF THE GOODS, OR THE FITNESS OF THE GOODS FOR A PARTICULAR PURPOSE. Adjustment to conform to actual conditions of usage may be required. Hospira assumes no responsibility for results obtained or for incidental or consequential damages, including lost profits, arising from the use of these data. No warranty against infringement of any patent, copyright or trademark is made or implied.